Cargando…

Development of a Physiologically Based Pharmacokinetic Model for Nitrofurantoin in Rabbits, Rats, and Humans

Nitrofurantoin (NFT) is a commonly used antibiotic for the treatment of urinary tract infections that can cause liver toxicity. Despite reports of hepatic adverse events associated with NFT exposure, there is still limited understanding of the interplay between NFT exposure, its disposition, and the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma, Raju Prasad, Burgers, Elsje J., Beltman, Joost B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535763/ https://www.ncbi.nlm.nih.gov/pubmed/37765169 http://dx.doi.org/10.3390/pharmaceutics15092199

Ejemplares similares

Stimulation of de novo glutathione synthesis by nitrofurantoin for enhanced resilience of hepatocytes
por: Wijaya, Lukas S., et al.
Publicado: (2021)

Development and validation of a physiology-based model for the prediction of pharmacokinetics/toxicokinetics in rabbits
por: Mavroudis, Panteleimon D., et al.
Publicado: (2018)

Reproductive toxicology. Nitrofurantoin.
Publicado: (1997)

Investigation of simplified physiologically‐based pharmacokinetic models in rat and human
por: Yau, Estelle, et al.
Publicado: (2023)

Relapsing nitrofurantoin-induced pneumonitis
por: Turner, Richard D., et al.
Publicado: (2011)

Physiologically based pharmacokinetic modeling of tea catechin mixture in rats and humans
por: Law, Francis C. P., et al.
Publicado: (2017)

Pharmacokinetic Characterization of Supinoxin and Its Physiologically Based Pharmacokinetic Modeling in Rats
por: Song, Yoo-Kyung, et al.
Publicado: (2021)

Fosfomycin versus Nitrofurantoin for the Treatment of Lower UTI in Outpatients
por: Sharma, Shraddha, et al.
Publicado: (2021)

Development of Inhalable Spray Dried Nitrofurantoin Formulations for the Treatment of Emphysema
por: Leslie, Mathew N., et al.
Publicado: (2022)

Nitrofurantoin methanol monosolvate
por: Vangala, Venu R., et al.
Publicado: (2011)

Nitrofurantoin‐induced acute pulmonary toxicity
por: Livanios, Konstantinos, et al.
Publicado: (2016)

Nitrofurantoin induced interstitial lung disease
por: Naidu, G. D., et al.
Publicado: (2014)

Nitrofurantoin-induced radiation recall dermatitis
por: Garrahy, Ian, et al.
Publicado: (2019)

Development of a Physiologically-Based Pharmacokinetic Model of the Rat Central Nervous System
por: Badhan, Raj K. Singh, et al.
Publicado: (2014)

Development of Physiologically Based Pharmacokinetic Model for Orally Administered Fexuprazan in Humans
por: Jeong, Yoo-Seong, et al.
Publicado: (2021)

Human physiologically based pharmacokinetic model for propofol
por: Levitt, David G, et al.
Publicado: (2005)

In Vitro and in Vivo Effects of Nitrofurantoin on Experimental Toxoplasmosis
por: Yeo, Seon-Ju, et al.
Publicado: (2016)

Consider Nitrofurantoin as a Cause of Lung Injury
por: Almeida, Paulo, et al.
Publicado: (2019)

Molecular mechanisms of collateral sensitivity to the antibiotic nitrofurantoin
por: Roemhild, Roderich, et al.
Publicado: (2020)

Assessment of Nitrofurantoin as an Experimental Intracanal Medicament in Endodontics
por: Alrahman, Mewan Salahalddin A., et al.
Publicado: (2020)

Systemic Inflammatory Response Syndrome Secondary to Nitrofurantoin
por: McGarry, Molly R., et al.
Publicado: (2021)

Nitrofurantoin-Associated Acute Granulomatous Interstitial Nephritis
por: Anupama, B. K., et al.
Publicado: (2021)

Nitrofurantoin: Interstitial lung disease: case report
Publicado: (2021)

Nitrofurantoin: what is the evidence for current UK guidance?
por: Kashouris, Eleanor, et al.
Publicado: (2023)

Predicting Resolvin D1 Pharmacokinetics in Humans with Physiologically‐Based Pharmacokinetic Modeling
por: Yellepeddi, Venkata K., et al.
Publicado: (2020)

Nitrofurantoin-induced pulmonary fibrosis: a case report
por: Goemaere, Natascha NT, et al.
Publicado: (2008)

Autoimmune hepatitis triggered by nitrofurantoin: a case series
por: Appleyard, Sally, et al.
Publicado: (2010)

Nitrofurantoin Toxicity: A Near Case of Mistaken Identity
por: Miskoff, Jeffrey A, et al.
Publicado: (2018)

Nitrofurantoin—Microbial Degradation and Interactions with Environmental Bacterial Strains
por: Pacholak, Amanda, et al.
Publicado: (2019)

In Vitro and In Vivo Trypanocidal Efficacy of Synthesized Nitrofurantoin Analogs
por: Munsimbwe, Linous, et al.
Publicado: (2021)

Drug-induced haemolysis: another reason to be cautious with nitrofurantoin
por: Bhatt, Chaitanya, et al.
Publicado: (2023)

Nitrofurantoin-Induced Exfoliative Dermatitis: A Case Report
por: Morna, Carolina, et al.
Publicado: (2022)

O02 Nitrofurantoin: what is the evidence for current guidance?
por: Kashouris, Eleanor, et al.
Publicado: (2023)

Integration of Physiologically-Based Pharmacokinetic Modeling into Early Clinical Development: An Investigation of the Pharmacokinetic Nonlinearity
por: Zhou, L, et al.
Publicado: (2015)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Metabolic Pathways of Bromochloromethane in Rats
por: Cuello, W. S., et al.
Publicado: (2012)

A physiologically-based pharmacokinetic model of oseltamivir phosphate and its carboxylate metabolite for rats and humans
por: Gao, Guanghua, et al.
Publicado: (2019)

Physiologically Based Pharmacokinetic Modeling and Simulation in Pediatric Drug Development
por: Maharaj, A R, et al.
Publicado: (2014)

Influence of aprepitant on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits
por: Kura, Raghunandan Reddy, et al.
Publicado: (2018)

An assessment of the role of redox cycling in mediating the toxicity of paraquat and nitrofurantoin.
por: Adam, A, et al.
Publicado: (1990)

Drug reaction with eosinophilia and systemic symptoms syndrome associated with Nitrofurantoin
por: Singh, Jitendra, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_38fjjfkei0lmvdeilpaa3u36jm